Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study
1998
Abstract Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls ( P P P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
30
References
2
Citations
NaN
KQI